Beyond anticoagulation: defining the role of left atrial appendage closure in stroke prevention for atrial fibrillation

Q: What is the clinical evidence from this study?

Study design: Review. Population: Atrial fibrillation at elevated thromboembolic risk. Intervention: Left atrial appendage closure (LAAC) vs. Oral anticoagulation (OAC) including direct oral anticoagulants (DOACs) and vitamin K antagonists. Primary outcome: Stroke and systemic embolism prevention.

Q: What does this research mean for the field?

Left atrial appendage closure should be reserved for individualized indications such as non-reversible contraindications to oral anticoagulation, treatment refusal, or cardioembolic stroke occurring despite adequate anticoagulation. Novelty: ClaimNovelty.INCREMENTAL. Consensus alignment: ConsensusAlignment.NEUTRAL.

A. John Camm

doi:10.1093/europace/euag296

October 15, 2026EP EuropaceOpen Access

Beyond anticoagulation: defining the role of left atrial appendage closure in stroke prevention for atrial fibrillation

View Full Paper

Ask AI

Bookmark

Share

Key result

Left atrial appendage closure should be reserved for appropriately selected atrial fibrillation patients with non-reversible contraindications to, refusal of, or intolerance to oral anticoagulation.

Figures

Graphical abstract published by EP Europace — Graphical abstract · Published by EP Europace · CC BY

Why the study?

Oral anticoagulation for AF carries limitations including residual ischaemic stroke, major bleeding, and discontinuation, while the appropriate role of left atrial appendage closure remains controversial, particularly in patients who tolerate anticoagulation.

Does left atrial appendage closure (LAAC) provide a safe and effective alternative or adjunct to oral anticoagulation for stroke prevention in selected patients with atrial fibrillation?

Key Points

To define the clinical role of left atrial appendage closure as an alternative or adjunct to oral anticoagulation for stroke prevention in patients with atrial fibrillation.
Clinical viewpoint and narrative synthesis analyzing registry and clinical trial evidence regarding oral anticoagulation limitations, bleeding risks, and left atrial appendage closure outcomes.
Evaluation of patient phenotypes including absolute contraindications, non-persistence, treatment refusal, and breakthrough ischaemic stroke while on anticoagulation therapy.
In surgical occlusion (LAAOS III trial, N=4811), stroke and systemic embolism were reduced from 7.0% to 4.8% (HR, 0.67; 95% CI, 0.53–0.85; P=0.001) at a mean follow-up of 3.8 years.
In registry data of patients post-discharge after gastrointestinal bleeding (PERSEO registry, N=70 of 1041 undergoing closure), intervention was associated with a lower risk of composite recurrent events (HR, 0.57; 95% CI, 0.37–0.89; P=0.013) and all-cause mortality (HR, 0.40; 95% CI, 0.22–0.72; P=0.002).
Breakthrough ischaemic strokes on anticoagulation stem from multiple etiologies, with approximately 25% attributed to competing mechanisms, 30% to insufficient anticoagulation, and 45% to cardioembolism despite adequate therapy.

Structured PICO

Does left atrial appendage closure (LAAC) provide a safe and effective alternative or adjunct to oral anticoagulation for stroke prevention in selected patients with atrial fibrillation?

P

Population

Patients with atrial fibrillation at elevated thromboembolic risk who have non-reversible contraindications to, refuse, or do not tolerate long-term oral anticoagulation.

I

Intervention

Left atrial appendage closure (LAAC), including percutaneous device implantation and surgical occlusion

C

Comparator

Oral anticoagulation (OAC), primarily direct oral anticoagulants (DOACs) or vitamin K antagonists

Limitations

Evidence for LAAC in patients with prior intracranial hemorrhage or specific high-risk subgroups remains largely observational and requires randomized confirmation.
LAAC does not eliminate antithrombotic treatment immediately, as most patients require short-term post-implant anticoagulation or antiplatelet therapy.
LAAC carries significant procedural risks including pericardial effusion, vascular injury, device-related thrombus, and peri-procedural stroke.
Much of the evidence supporting broader indications for LAAC (such as in prior intracranial haemorrhage or after gastrointestinal bleeding) remains observational and requires formal randomized confirmation.
LAAC does not immediately eliminate the need for antithrombotic treatment, as most patients require a post-implantation period of anticoagulation and/or antiplatelet therapy.
LAAC cannot prevent ischaemic strokes arising from non-cardioembolic competing mechanisms (e.g., large-artery atherosclerosis or small-vessel disease).

Ask about this paper

Answers are grounded in this paper and cite their sources.

Implication

This viewpoint outlines an individualized framework for selecting patients with atrial fibrillation for left atrial appendage closure, emphasizing the need to distinguish irreversible contraindications to oral anticoagulation from modifiable bleeding risks, non-adherence, and non-cardioembolic breakthrough strokes.

Abstract

Oral anticoagulation has a very strong evidence base for stroke prevention in patients with atrial fibrillation (AF) at elevated thromboembolic risk. Direct oral anticoagulants have improved the safety and convenience of treatment, yet important limitations remain, including residual ischaemic stroke, major bleeding, treatment discontinuation, and patient refusal. Left atrial appendage closure (LAAC) offers an alternative strategy for selected patients by excluding the principal anatomical source of AF-related cardiac thrombi. However, the appropriate role of LAAC remains controversial, particularly in patients who can and do tolerate anticoagulation. This viewpoint argues for a more individualized approach that distinguishes absolute contraindications from modifiable bleeding risks, treatment refusal or non-persistence, and stroke occurring despite adequate anticoagulation.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

A. John Camm (2026) conducted a review in Atrial fibrillation at elevated thromboembolic risk. Left atrial appendage closure (LAAC) vs. Oral anticoagulation (OAC) including direct oral anticoagulants (DOACs) and vitamin K antagonists was evaluated on Stroke and systemic embolism prevention. Left atrial appendage closure should be reserved for appropriately selected atrial fibrillation patients with non-reversible contraindications to, refusal of, or intolerance to oral anticoagulation.

synapsesocial.com/papers/6aefbd4950d2071ffda4bc44 https://doi.org/10.1093/europace/euag296

View Full Paper

Ask AI

Bookmark

Share

Beyond anticoagulation: defining the role of left atrial appendage closure in stroke prevention for atrial fibrillation

Figures

Key Points

Structured PICO

Limitations

Ask about this paper

Implication

Abstract

Discussion

Cite This Study

Beyond anticoagulation: defining the role of left atrial appendage closure in stroke prevention for atrial fibrillation

Figures

Key Points

Structured PICO

Limitations

Ask about this paper

Implication

Abstract

Discussion

Cite This Study

Keep reading

Keep reading